瑞普替尼 T8482

Product Introduction
Bioactivity


英文名: Ripretinib

描述: Ripretinib (DCC-2618) 是一种口服生物利用的，选择性 KIT 和 PDGFRA 开关控制抑制剂，具有抗肿瘤作用并诱导细胞凋亡。它专门针对 KIT 和 PDGFRA 的野生型和突变型并与之结合在其开关口袋结合位点，从而防止这些激酶从无活性构象转变为有活性构象，并使它们的野生型和突变体形式失活。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 40 mg/mL(78.38 mM)


关键字: c-Kit | Inhibitor | Vascular endothelial growth factor receptor | CD135 | CD117 | Platelet-derived growth factor receptor | VEGFR | PDGFR | inhibit | Ripretinib | Apoptosis | Cluster of differentiation antigen 135 | SCFR | Fms like tyrosine kinase 3 | FLT3 | DCC2618 | DCC 2618

相关产品: Luminespib | JX06 | Nebivolol hydrochloride | Cl-amidine hydrochloride | Acitretin | saponaretin | fac-[Re(CO)3(L6)(H2O)][NO3] | Oenothein B | Limonin | YUM70

相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Tyrosine Kinase Inhibitor Library | EMA Approved Drug Library

瑞普替尼 T8482信息由TargetMol中国为您提供，如您想了解更多关于瑞普替尼 T8482报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途